When science and AI converge- the evolving landscape of Pulmonary Arterial Hypertension (PAH) care – webinar, slides, and transcript

Download the slides Co-design of digital interventions Teleconsultations and remote follow-up in clinical practice  Home monitoring devices and wearables Innovations in drug delivery to improve the patient experience In this first quarterly webinar we were joined by leading experts and a patient advocate to explore how AI, digital health, remote monitoring, and new treatment approaches […]

When science and AI converge- the evolving landscape of Pulmonary Arterial Hypertension (PAH) care – webinar, slides, and transcript Read Post »

The hidden cost of pulmonary arterial hypertension (PAH): quantifying work productivity loss in working-age adults, Journal of Medical Economy, March 5, 2026

Using US health insurance data from 2019 to 2023, a study recently published in the Journal of Medical Economy quantified the number of workdays lost annually by working-age adults with pulmonary arterial hypertension due to medical appointments and care. The cost of this lost productivity was estimated using average household income as a benchmark. The

The hidden cost of pulmonary arterial hypertension (PAH): quantifying work productivity loss in working-age adults, Journal of Medical Economy, March 5, 2026 Read Post »

Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), an European Society of Cardiology (ESC) scientific statement, European Journal of Heart Failure, March 9, 2026

A scientific statement of the European Society of Cardiology Working Group on Pulmonary Circulation & Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease (PAH-CHD), and the Association of Cardiovascular Nursing & Allied Professions of the ESC was recently published in the European Journal of Heart Failure. The authors say that current

Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), an European Society of Cardiology (ESC) scientific statement, European Journal of Heart Failure, March 9, 2026 Read Post »

Assessing the feasibility of using smartphone data to identify risk of idiopathic pulmonary arterial hypertension, NPJ Vascular Health, March 25, 2026

A UK pilot study explored whether physical activity data from wearable devices and a smartphone app (My Heart Counts) could help detect idiopathic pulmonary arterial hypertension (IPAH) earlier, before formal diagnosis. Analysing up to eight years of real-world activity and heart rate data from 109 participants, including patients with idiopathic pulmonary arterial hypertension, disease controls,

Assessing the feasibility of using smartphone data to identify risk of idiopathic pulmonary arterial hypertension, NPJ Vascular Health, March 25, 2026 Read Post »

Defining quality standards of care in Connective Tissue Disease-Pulmonary Arterial Hypertension (CTD-PAH) and management best practices: a Delphi panel consensus, Rheumatology Advances in Practice, January 2026

A European Delphi panel involving 24 healthcare professionals from six countries reached consensus on best practices for managing pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH), particularly systemic sclerosis (SSc). Key areas of agreement included the importance of multimodal screening combining echocardiography, biomarkers and symptom evaluation, better access to echocardiography, and a multidisciplinary approach

Defining quality standards of care in Connective Tissue Disease-Pulmonary Arterial Hypertension (CTD-PAH) and management best practices: a Delphi panel consensus, Rheumatology Advances in Practice, January 2026 Read Post »

Cereno Scientific receives approval to initiate FDA-aligned Phase I pharmacokinetic study of CS014 supporting Phase II development in pulmonary hypertension associated with interstitial lung diseases (PH-ILD)

Swedish biotech Cereno Scientific has received approval from the Swedish Medical Products Agency to begin a Phase I study of its experimental drug CS014, a new HDAC inhibitor being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study, designed in line with FDA guidance, will compare CS014’s pharmacokinetics to valproic acid (VPA),

Cereno Scientific receives approval to initiate FDA-aligned Phase I pharmacokinetic study of CS014 supporting Phase II development in pulmonary hypertension associated with interstitial lung diseases (PH-ILD) Read Post »

The UK Pulmonary Hypertension Association’s free resource of the month, “Driving with pulmonary hypertension”, March 2026

The aim of this publication is to guide patients through the process of notifying the Driver and Vehicle Licensing Agency of your pulmonary hypertension, answer some of the common questions we hear, and help you understand what to expect along the way. Read more at this link on the PHA UK website

The UK Pulmonary Hypertension Association’s free resource of the month, “Driving with pulmonary hypertension”, March 2026 Read Post »

Impact of smoking on diagnosis and survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients, Pulmonology, 2026

Exposure to cigarette smoke is a well-recognised risk factor for endothelial dysfunction, which causes changes in pulmonary vascular architecture and can lead to pulmonary hypertension — and notably, these changes occur at an early stage of smoking-related lung disease, long before airway obstruction develops. Despite this, the specific impact of smoking on pulmonary arterial hypertension

Impact of smoking on diagnosis and survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients, Pulmonology, 2026 Read Post »

Study links allergy molecule to worsening heart function in pulmonary arterial hypertension, Pulmonary Hypertension News, March 11, 2026

A study published in Pulmonary Circulation and reported in the March 11 issue of Pulmonary Hypertension News, has found that higher blood levels of immunoglobulin E (IgE) — an immune molecule normally associated with allergies — are linked to worse right heart function in pulmonary arterial hypertension patients. Those with elevated IgE levels showed more

Study links allergy molecule to worsening heart function in pulmonary arterial hypertension, Pulmonary Hypertension News, March 11, 2026 Read Post »

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list

Martine Aliana Rothblatt (born 1954) is an American lawyer, author, and entrepreneur. She founded United Therapeutics in 1996, to make medicines for her daughter who suffered from pulmonary arterial hypertension, and is now developing genetically modified pig organs for human transplant. On the latter topic she has written a book titled “Your life or mine

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list Read Post »

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026

Since sotatercept received Food and Drug Administration (FDA) approval for pulmonary arterial hypertension in March 2024, knowing when and how to use it has become an essential part of managing this serious condition — so say the authors of a recently published article in CHEST, who offer a practical guide for clinicians navigating this new

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026 Read Post »

A Proof of Concept for the Use of Lung Ultrasound in the Diagnostic Approach of Pulmonary Hypertension, CHEST, March 2026

The authors of a study recently published on CHEST retrospectively analyzed data from adult patients enrolled in the French Pulmotension registry (Commission Nationale de l’Informatique et des Libertés No. 842063) from the Limoges Competence Center between May 1, 2020, and May 1, 2021. Inclusion criteria were the following: (1) confirmed pulmonary hypertension (PH) diagnosed by

A Proof of Concept for the Use of Lung Ultrasound in the Diagnostic Approach of Pulmonary Hypertension, CHEST, March 2026 Read Post »

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026

This review covers the full clinical picture of pulmonary arterial hypertension (PAH) — from its pathophysiology and diagnosis through to current and emerging treatments. Understanding the Disease Pulmonary arterial hypertension is driven by progressive structural remodelling of the pulmonary arteries, creating a vicious cycle of vasoconstriction, inflammation, and uncontrolled cell growth that ultimately leads to

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026 Read Post »

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026

A Japanese study has confirmed that sotatercept works just as well in Asian patients, even though pulmonary arterial hypertension presents somewhat differently in the Asian population: patients tend to have longer disease duration, more severe baseline profiles, and are more frequently on intensive triple therapy including parenteral prostacyclin. This was a regional Phase 3, open-label

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026 Read Post »

European Society of Cardiology (ESC) announces launch of the plain language version of the guidelines on cardio-vascular disease in pregnancy on March 8, 2026, International Women’s Day

This International Women’s Day, the European Society of Cardiology (ESC) proudly announced the launch of the patient version of the 2025 guidelines on the management of cardiovascular disease (CVD) in pregnancy. Pregnancy is a life-changing experience — but for women living with cardiovascular disease, it comes with an additional layer of complexity, uncertainty, and anxiety.

European Society of Cardiology (ESC) announces launch of the plain language version of the guidelines on cardio-vascular disease in pregnancy on March 8, 2026, International Women’s Day Read Post »

Methamphetamine-Associated pulmonary arterial hypertension: a growing and distinct patient population, Journal of Heart and Lung Transplant, March 5, 2026

A large US claims-based study has shed light on a worrying trend: pulmonary arterial hypertension linked to methamphetamine use (Meth-APAH) is rising fast — up 93% between 2018 and 2022, a rate disproportionate to the general rise in methamphetamine use itself. Compared to other pulmonary arterial hypertension patients, those with Meth-APAH tend to be younger,

Methamphetamine-Associated pulmonary arterial hypertension: a growing and distinct patient population, Journal of Heart and Lung Transplant, March 5, 2026 Read Post »

Video recording & full transcript (translatable in 40 languages) now available for the Pulmonary Hypertension Expert Patient Academy (PHEPA) joint Alliance for Pulmonary Hypertension and PHA Europe project

LINK TO VIDEO TRANSCRIPT Can be translated in 40 languges, check orange button on bottom of page Gergely Meszaros: Good evening and good afternoon to everyone. Welcome to this webinar introducing the Pulmonary Hypertension Expert Patient Academy (PHEPA). I’m delighted to present this new initiative. When ERN-LUNG, the European Reference Network for Rare Respiratory Diseases,

Video recording & full transcript (translatable in 40 languages) now available for the Pulmonary Hypertension Expert Patient Academy (PHEPA) joint Alliance for Pulmonary Hypertension and PHA Europe project Read Post »

United Therapeutics announces results for its Phase 3 ADVANCE OUTCOMES study on ralenipag for pulmonary arterial hypertension, March 2, 2026

United Therapeutics has announced promising results from its pivotal Phase 3 ADVANCE OUTCOMES study of ralinepag, a new oral treatment for pulmonary arterial hypertension (PAH). Ralinepag is a highly selective prostacyclin (IP) receptor agonist that works through multiple pathways — vasodilatory, anti-proliferative, and anti-inflammatory. It is taken once daily orally, yet achieves sustained receptor activity

United Therapeutics announces results for its Phase 3 ADVANCE OUTCOMES study on ralenipag for pulmonary arterial hypertension, March 2, 2026 Read Post »

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026

A consensus document featuring 10 statements, the main focus of which was the use of parenteral prostanoids, was developed by eight experts in pulmonary arterial hypertension during in-person and web-based meetings. Forty-six Italian physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement. These consensus statements are intended to support physicians

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026 Read Post »

Nippon Shinyaku reports progress on trials on NS-863 targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Nippon Shinyaku recently reported progress on two Phase 2 trials of its oral candidate NS-863, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), both serious cardiopulmonary conditions with high unmet need. By advancing NS-863 across two related indications, the company is signaling a deeper push into rare cardiopulmonary therapeutics,

Nippon Shinyaku reports progress on trials on NS-863 targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) Read Post »

TRANSLATE »
Scroll to Top